Akèy › Limfòm Non-Hodgkin › Ohio › Cleveland
Etid klinik pou Limfòm Non-Hodgkin nan Cleveland, OH
13 etid pou Limfòm Non-Hodgkin ap chèche patisipan nan sit nan ak bò kote Cleveland (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
T-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)
Ap rekriteFaz 1/2
- University Hospitals Seidman Cancer Center, Cleveland
A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
Ap rekriteFaz 1
- Cleveland Clinic, Cleveland
Rituximab (Rtx) + Tafasitamab in Combination With Allogeneic NK Cells for Treatment of Relapsed/Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)
Ap rekriteFaz 1
- Case Comprehensive Cancer Center, University Hospitals Seidman Cancer Center, Cleveland
- Case Comprehensive Cancer Center, Cleveland Clinic Foundation Taussig Cancer Institute, Cleveland
A Study of ARV-393 in Relapsed/Refractory Non-Hodgkin Lymphoma.
Ap rekriteFaz 1
- Clinical Trial Site, Cleveland
Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma
Ap rekriteFaz 1/2
- Cleveland Clinic, Cleveland
A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy
Ap rekriteFaz 3
- Cleveland Clinical Taussig Cancer Center, Cleveland
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
Ap rekriteEtid obsèvasyon
- University Hospitals Case Medical Center, Cleveland
- Cleveland Clinic, Cleveland
Study of Cytokine Release Syndrome Prophylaxis and Treatment With Siltuximab Prior to Epcoritamab
Ap rekriteFaz 1
- Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center, Cleveland
CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
Ap rekriteFaz 1/2
- Cleveland Clinic, Cleveland
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Ap rekriteEtid obsèvasyon
- Massive Bio SYNERGY-AI site, Mayfield Heights · 12 mi lwen
A Study of AC676 for the Treatment of Relapsed/Refractory B-Cell Malignancies
Ap rekriteFaz 1
- University Hospitals Cleveland Medical Center, Cleveland
IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers
Ap rekriteFaz 1/2
- University Hospitals Cleveland, Cleveland
Phase 1 Study of BAFF CAR-T Cells (LMY-920) for Non-Hodgkin Lymphoma
Ap rekriteFaz 1
- University Hospitals Seidman Cancer Center, Cleveland
- Taussig Cancer Institute | Cleveland Clinic, Cleveland
Etid Limfòm Non-Hodgkin nan lòt vil
- New York City, NY31 etid
- Houston, TX31 etid
- Boston, MA26 etid
- Nashville, TN21 etid
- Philadelphia, PA20 etid
- Baldwin Park, CA19 etid
- Washington, DC18 etid
- Chicago, IL18 etid
- Milwaukee, WI18 etid
- Atlanta, GA18 etid
- Columbus, OH18 etid
- Dallas, TX17 etid
Lòt etid nan Cleveland
- Kansè Poumon ki pa ti selil43 etid
- Kansè (tout kalite)36 etid
- Kansè nan tete35 etid
- Kansè pwostat34 etid
- Ensifizyans kadyak33 etid
- Kansè ovè30 etid
- Kansè Metastatik30 etid
- Kansè poumon26 etid
- Kansè kolorektal24 etid
- Maladi kadyovaskilè22 etid
- Kansè Endomèt20 etid
- Leksemi mieloïd egi20 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 6, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.